Designed biosynthesis of 25-methyl and 25-ethyl ivermectin with enhanced insecticidal activity by domain swap of avermectin polyketide synthase
Tóm tắt
Avermectin and milbemycin are important 16-membered macrolides that have been widely used as pesticides in agriculture. However, the wide use of these pesticides inevitably causes serious drug resistance, it is therefore imperative to develop new avermectin and milbemycin analogs. The biosynthetic gene clusters of avermectin and milbemycin have been identified and the biosynthetic pathways have been elucidated. Combinatorial biosynthesis by domain swap provides an efficient strategy to generate chemical diversity according to the module polyketide synthase (PKS) assembly line. The substitution of aveDH2-KR2 located in avermectin biosynthetic gene cluster in the industrial avermectin-producing strain Streptomyces avermitilis NA-108 with the DNA regions milDH2-ER2-KR2 located in milbemycin biosynthetic gene cluster in Streptomyces bingchenggensis led to S. avermitilis AVE-T27, which produced ivermectin B1a with high yield of 3450 ± 65 μg/ml. The subsequent replacement of aveLAT-ACP encoding the loading module of avermectin PKS with milLAT-ACP encoding the loading module of milbemycin PKS led to strain S. avermitilis AVE-H39, which produced two new avermectin derivatives 25-ethyl and 25-methyl ivermectin (1 and 2) with yields of 951 ± 46 and 2093 ± 61 μg/ml, respectively. Compared to commercial insecticide ivermectin, the mixture of 25-methyl and 25-ethyl ivermectin (2:1 = 3:7) exhibited 4.6-fold increase in insecticidal activity against Caenorhabditis elegans. Moreover, the insecticidal activity of the mixture of 25-methyl and 25-ethyl ivermectin was 2.5-fold and 5.7-fold higher than that of milbemycin A3/A4 against C. elegans and the second-instar larva of Mythimna separate, respectively. Two new avermectin derivatives 25-methyl and 25-ethyl ivermectin were generated by the domain swap of avermectin PKS. The enhanced insecticidal activity of 25-methyl and 25-ethyl ivermectin implied the potential use as insecticide in agriculture. Furthermore, the high yield and genetic stability of the engineered strains S. avermitilis AVE-T27 and AVE-H39 suggested the enormous potential in industrial production of the commercial insecticide ivermectin and 25-methyl/25-ethyl ivermectins, respectively.
Tài liệu tham khảo
Lim LE, Vilchèze C, Ng C, Jacobs WR Jr, Ramón-García S, Thompson CJ. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother. 2013;57:1040–6.
Thuan NH, Pandey RP, Sohng JK. Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives. Appl Microbiol Biotechnol. 2014;98:7747–59.
Zhou Y, Zhang T, Wang Q, Cruz-Morales P, Zhang B, Liu M, Barona-Gómez F, Zhang L. Synthetic biology of avermectin for production improvement and structure diversification. Biotechnol J. 2014;9:316–25.
Ōmura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445–55.
Lumaret J-P, Errouissi F, Floate K, Römbke J, Wardhaugh K. A review on the toxicity and non-target effects of macrocyclic lactones in terrestrial and aquatic environments. Curr Pharm Biotechnol. 2012;13:1004–60.
Li M, Chen Z, Lin X, Zhang X, Song Y, Wen Y, Li J. Engineering of avermectin biosynthetic genes to improve production of ivermectin in Streptomyces avermitilis. Bioorg Med Chem Lett. 2008;18:5359–63.
Wang H-Y, Zhang J, Zhang Y-J, Zhang B, Liu C-X, He H-R, Wang X-J, Xiang W-S. Combined application of plasma mutagenesis and gene engineering leads to 5-oxomilbemycins A3/A4 as main components from Streptomyces bingchenggensis. Appl Microbiol Biotechnol. 2014;98:9703–12.
Zhang X, Chen Z, Li M, Wen Y, Song Y, Li J. Construction of ivermectin producer by domain swaps of avermectin polyketide synthase in Streptomyces avermitilis. Appl Microbiol Biotechnol. 2006;72:986–94.
Frasch H-J, Medema MH, Takano E, Breitling R. Design-based re-engineering of biosynthetic gene clusters: plug-and-play in practice. Curr Opin Biotechnol. 2013;24:1144–50.
Wong FT, Khosla C. Combinatorial biosynthesis of polyketides—a perspective. Curr Opin Chem Biol. 2012;16:117–23.
Gaisser S, Kellenberger L, Kaja AL, Weston AJ, Lill RE, Wirtz G, Kendrew SG, Low L, Sheridan RM, Wilkinson B, Galloway IS, Stutzman-Engwall K, McArthur HAI, Staunton J, Leadlay PF. Direct production of ivermectin-like drugs after domain exchange in the avermectin polyketide synthase of Streptomyces avermitilis ATCC31272. Org Biomol Chem. 2003;1:2840–7.
Cropp TA, Wilson DJ, Reynolds KA. Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin. Nat Biotechnol. 2000;18:980–3.
Wang J-B, Pan H-X, Tang G-L. Production of doramectin by rational engineering of the avermectin biosynthetic pathway. Bioorg Med Chem Lett. 2011;21:3320–3.
Wang X-J, Yan Y-J, Zhang B, An J, Wang J-J, Tian J, Jiang L, Chen Y-H, Huang S-X, Yin M, Zhang J, Gao A-L, Liu C-X, Zhu Z-X, Xiang W-S. Genome sequence of the milbemycin-producing bacterium Streptomyces bingchenggensis. J Bacteriol. 2010;192:4526–7.
Wang X-J, Zhang B, Yan Y-J, An J, Zhang J, Liu C-X, Xiang W-S. Characterization and analysis of an industrial strain of Streptomyces bingchenggensis by genome sequencing and gene microarray. Genome. 2013;56:677–89.
Albers-Schönberg G, Arison BH, Chabala JC, Douglas AW, Eskola P, Fisher MH, Lusi A, Mrozik H, Smith JL, Tolman RL. Avermectins. Structure determination. J Am Chem Soc. 1981;103:4216–21.
Wang X-J, Zhang J, Wang J-D, Huang S-X, Chen Y-H, Liu C-X, Xiang W-S. Four new doramectin congeners with acaricidal and insecticidal activity from Streptomyces avermitilis NEAU1069. Chem Biodivers. 2011;8:2117–25.
Chabala JC, Mrozik H, Tolman RL, Eskola P, Lusi A, Peterson LH, Woods MF, Fisher MH. Ivermectin, a new broad-spectrum antiparasitic agent. J Med Chem. 1980;23:1134–6.
Lanusse C, Lifschitz A, Virkel G, Alvarez L, Sánchez S, Sutra JF, Galtier P, Alvinerie M. Comparative plasma disposition kinetic of ivermectin, moxidectin and doramectin in cattle. J Vet Pharmacol Ther. 1997;20:91–9.
dos Santos AR, Falcäo CAB, Muzitano MF, Kaiser CR, Rossi-Bergmann B, Férézou J-P. Ivermectin-derived leishmanicidal compounds. Bioorg Med Chem. 2009;17:496–502.
Pitterna T, Cassayre J, Hüter OF, Jung PMJ, Maienfisch P, Kessabi FM, Quaranta L, Tobler H. New ventures in the chemistry of avermectins. Bioorg Med Chem. 2009;17:4085–95.
Zhang J, An J, Wang J-J, Yan Y-J, He H-R, Wang X-J, Xiang W-S. Genetic engineering of Streptomyces bingchenggensis to produce milbemycins A3/A4 as main components and eliminate the biosynthesis of nanchangmycin. Appl Microbiol Biotechnol. 2013;97:10091–101.
Zhao J-H, Xu X-J, Ji M-H, Cheng J-L, Zhu G-N. Design, synthesis, and biological activities of milbemycin analogues. J Agric Food Chem. 2011;59:4836–50.
Williams GJ. Engineering polyketide synthases and nonribosomal peptide synthetases. Curr Opin Struct Biol. 2013;23:603–12.
Li J, Li L, Feng C, Chen Y, Tan H. Novel polyoxins generated by heterologously expressing polyoxin biosynthetic gene cluster in the sanN inactivated mutant of Streptomyces ansochromogenes. Microb Cell Fact. 2012;11:135.
Weissman KJ, Leadlay PF. Combinatorial biosynthesis of reduced polyketides. Nat Rev Microbiol. 2005;3:925–36.
Sun P, Zhao Q, Yu F, Zhang H, Wu Z, Wang Y, Wang Y, Zhang Q, Liu W. Spiroketal formation and modification in avermectin biosynthesis involves a dual activity of AveC. J Am Chem Soc. 2013;135:1540–8.
Yoon YJ, Kim E-S, Hwang Y-S, Choi C-Y. Avermectin: biochemical and molecular basis of its biosynthesis and regulation. Appl Microbiol Biotechnol. 2004;63:626–34.
Yoon YJ, Beck BJ, Kim BS, Kang H-Y, Reynolds KA, Sherman DH. Generation of multiple bioactive macrolides by hybrid modular polyketide synthases in Streptomyces venezuelae. Chem Biol. 2002;9:203–14.
Gregory MA, Kaja AL, Kendrew SG, Coates NJ, Warneck T, Nur-Alam M, Lill RE, Sheehan LS, Chudley L, Moss SJ, Sheridan RM, Quimpere M, Zhang M-Q, Martin CJ, Wilkinson B. Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry. Chem Sci. 2013;4:1046–52.
Park SR, Han AR, Ban Y-H, Yoo YJ, Kim EJ, Yoon YJ. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol. 2010;85:1227–39.
Marsden AF, Wilkinson B, Cortés J, Dunster NJ, Staunton J, Leadlay PF. Engineering broader specificity into an antibiotic producing polyketide synthase. Science. 1998;279:199–202.
Sheehan LS, Lill RE, Wilkinson B, Sheridan RM, Vousden WA, Kaja AL, Crouse GD, Gifford J, Graupner PR, Karr L, Lewer P, Sparks TC, Leadlay PF, Waldron C, Martin CJ. Engineering of the spinosyn PKS: directing starter unit incorporation. J Nat Prod. 2006;69:1702–10.
Dutton CJ, Gibson SP, Goudie AC, Holdom KS, Pacey MS, Ruddock JC, BuʼLock JD, Richards MK. Novel avermectins produced by mutational biosynthesis. J Antibiot. 1991;44:357–65.
Meinke PT, O’Connor SP, Mrozik H, Fisher MH. Synthesis of ring-contracted, 25-nor-6,5-spiroketal-modified avermectin derivatives. Tetrahedron Lett. 1992;33:1203–6.
Shih TL, Mrozik H, Holmes MA, Fisher MH. A witting approach to novel C24 and C25-substituted avermectins. Tetrahedron Lett. 1990;31:3529–32.
Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. Practical streptomyces genetics. Norwich: John Innes Foundation Norwich; 2000.
Sambrook J, Fritsch T, Maniatis EF. Molecular cloning: a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
Wurch T, Lestienne F, Pauwels PJ. A modified overlap extension PCR method to create chimeric genes in the absence of restriction enzymes. Biotecnhol Tech. 1998;12:653–7.
Xiang W-S, Wang J-D, Wang M, Wang X-J. New nemadectin congener from Streptomyces microflavus neau3: fermentation, isolation, structure elucidation and biological activities. J Antibiot. 2010;63:171–5.